TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15607843
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose buprenorphine (HD, 8‐8‐8‐4‐2 mg/day on days 1‐5)
Study: 15607843
Drug: Clonidine (C,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (C, 0.2‐0.3‐0.3‐0.2‐0.1 mg QID on days 1‐5)
Study: 15607843
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose buprenorphine (HD)
Study: 7548807
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy for 1 week (Group IIa, n = 16)
Study: 7548807
Drug: No drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drugs (Group I, n = 29)
Study: 7548807
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (2 weeks) for patients whose ulcer recurred after nizatidine
Study: 2170104
Drug: Instant bean
Normalized name: Bean
DrugBank: Bean (DB14709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instant bean flakes (174 g/d)
Study: 2170104
Drug: Potato flakes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potato flakes (102 g/d)
Study: 6993442
Drug: Continuous radiation
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous radiation therapy (30 fractions of 220 rad each, total dose of 6600 rad)
Study: 20858487
Drug: BIBW 2948
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIBW 2948 BS (EGFR kinase domain inhibitor), inhalatively administered
Study: 20550864
Drug: Intrathecal isobaric
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal isobaric ropivacaine (15 mg)
Study: 11435650
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside (SNP) infusion in CPB
Study: 11435650
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of isoflurane inhalation (0.2-0.5%) + SNP in low doses (<1mg/kg/min)
Study: 8384887
Drug: ACTH1-24 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACTH1-24 (various doses)
Study: 31167889
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus Rosiglitazone (M + R)
Study: 20356587
Drug: Metformin (M)
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (M)
Study: 31167889
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus Lifestyle (M + L)
Study: 23518003
Drug: In-surgery bleaching
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-surgery bleaching with light activated 25% hydrogen peroxide gel followed by 2 weeks at home, night time bleaching with 10% carbamide peroxide gel in a customised bleaching tray.
Study: 23518003
Drug: In-surgery bleaching
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-surgery bleaching with 25% hydrogen peroxide without light activation followed by 2 weeks at home, night time bleaching with 10% carbamide peroxide gel in a customised bleaching tray.
Study: 9237092
Drug: Guided Imagery
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided Imagery and Music (GIM) therapy
Study: 7954026
Drug: Sustained-release isosorbide
Normalized name: isosorbide Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release isosorbide dinitrate (ISDN) 40 mg twice daily
Study: 29278279
Drug: Camicinal 50
Normalized name: Camicinal
DrugBank: Camicinal (DB12567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camicinal 50 mg once-daily
Study: 27421242
Drug: Azilsartan (AZL)
DrugBank: Azilsartan medoxomil (DB08822)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azilsartan (AZL) 5 mg
Study: 27421242
Drug: Azilsartan (AZL)
DrugBank: Azilsartan medoxomil (DB08822)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azilsartan (AZL) 10 mg
Study: 27421242
Drug: Azilsartan (AZL)
DrugBank: Azilsartan medoxomil (DB08822)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azilsartan (AZL) 20 mg
Study: 27421242
Drug: Azilsartan (AZL)
DrugBank: Azilsartan medoxomil (DB08822)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azilsartan (AZL) 40 mg
Study: 11440284
Drug: Telmisartan 40
Normalized name: telmisartan 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 40 mg/HCTZ 12.5 mg
Study: 11440284
Drug: Telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80 mg/HCTZ 12.5 mg
Study: 10569261
Drug: Abduction orthosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abduction orthosis treatment initiated at approximately 4 months of age in 6 cases with persisting dysplasia
Study: 10569261
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (87 children)
Study: 10569261
Drug: Abduction orthosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abduction orthosis treatment
Study: 29383480
Drug: BoNT-A prostatic
Normalized name: BoNT/A-DS
DrugBank: LetibotulinumtoxinA (DB16820)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BoNT-A prostatic injection (200 UI)
Study: 27221799
Drug: Optimized medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized medical therapy
Study: 29083439
Drug: n-3 PUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFA supplementation (DHA 800 mg and EPA 225 mg daily for 3 years)
Study: 29083439
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical capsules comprising liquid paraffin oil)
Study: 26266835
Drug: Transparent perfluorodecalin
Normalized name: Perfluorodecalin
DrugBank: Perfluorodecalin (DB16292)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transparent perfluorodecalin (PFD) infused patch with Q-switched Alexandrite laser (755 nm)
Study: 6755255
Drug: Less intense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less intense anticoagulant therapy (mean prothrombin time of 26.9 seconds, Simplastin time 15 seconds)
Study: 6755255
Drug: More intense
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More intense anticoagulant therapy (mean Simplastin time of 19.4 seconds, prothrombin time 41 seconds)
Study: 30513231
Drug: Stimulant and
Normalized name: norgestimate and ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant and non-stimulant treatments for ADHD
Study: 25350959
Drug: etravirine 200
Normalized name: etravirine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: etravirine 200 mg bid
Study: 15213060
Drug: Hypertonic NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic NaCl solution infusion (855 mmol/l) followed by free access to water
Study: 7653793
Drug: Propofol/alfentanil anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol/alfentanil anaesthesia (propofol 2 mg/kg, alfentanil 15 micrograms/kg, maintained by infusion of propofol and alfentanil)
Study: 25922978
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml bupivacaine
Study: 25922978
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml bupivacaine with 100 μg of fentanyl
Study: 25922978
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml bupivacaine with 100 ng naloxone
Study: 22030144
Drug: Foley catheter
Normalized name: Bard Foley Catheter 18FR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foley catheter (30 mL)
Study: 8610776
Drug: Vaginal prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal prostaglandin E2 gel
Study: 12722173
Drug: Spa therapy
Normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spa therapy for 3 weeks during a 20-week spa period
Study: 9189963
Drug: Placebo (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5 ml of water)
Study: 1552106
Drug: rt-PA (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: rt-PA (100 mg with an initial bolus dose of 15 mg followed by an infusion of 50 mg over 30 min and 35 mg over 60 min)
Study: 3910726
Drug: H142 (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: H142 (1.0 and 2.5 mg/kg per h)
Study: 17939171
Drug: Diltiazem (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (120 mg single dose)
Study: 16099718
Drug: 4.5 g
Normalized name: Zosyn 4.5 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5 g sodium oxybate nightly for 8 weeks
Study: 8578179
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg twice daily for 6 weeks
Study: 383276
Drug: Cyclophosphamide 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 600 mg/m2 IV on day 1 plus DTIC 200 mg/m2 IV days 1 through 5
Study: 383276
Drug: Cyclophosphamide 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 600 mg/m2 IV on day 1 plus DTIC 200 mg/m2 IV days 1 through 5 plus C. parvum 5 mg/m2 IV on day 8 and day 15
Study: 3653591
Drug: Diltiazem 240
Normalized name: diltiazem 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 240 mg/day
Study: 24695896
Drug: Vitamin D₃
Normalized name: vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D₃ (20 μg/d)
Study: 20389255
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate 100 mg eq.
Study: 19941696
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate (both doses)
Study: 12139269
Drug: Paracetamol 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 1000 mg plus codeine 30 mg
Study: 7041936
Drug: Paracetamol 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 1000 mg alone
Study: 9865013
Drug: Therapeutic plasmapheresis
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic plasmapheresis (TP) + alpha-tocopherol treatment (AT)
Study: 8560531
Drug: Artemether (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether (4 mg/kg/d for 3 d) + mefloquine (25 mg/kg)
Study: 8560531
Drug: Mefloquine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine alone (25 mg/kg)
Study: 350262
Drug: Propranolol, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol, 40 mg three times daily
Study: 28722100
Drug: Integrative-psychotherapeutic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative-psychotherapeutic treatment program consisting of 16 weekly sessions including vestibular rehabilitation training and modules for anxiety, panic disorder, depression, and somatisation.
Study: 26638592
Drug: Direct field
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct field block with 40 ml of 0.125% bupivacaine
Study: 26638592
Drug: Spinal block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal block with intrathecal morphine (Control)
Study: 17047615
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day atorvastatin
Study: 11005043
Drug: ECT with
Normalized name: Nexa Select with DHA
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECT with high dosage (2.5 times seizure threshold)
Study: 28535410
Drug: Perampanel 1mg
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Perampanel 1mg with ketoconazole 400mg once daily for 10 days
Study: 28535410
Drug: Ketoconazole 400mg
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconazole 400mg once daily for 10 days
Study: 28535410
Drug: Simulations with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simulations with a more potent inhibitor than ketoconazole (e.g., itraconazole)
Study: 24155139
Drug: Tocilizumab (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (intravenous dose based on body weight every 2 or 4 weeks)
Study: 16818571
Drug: Folate (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folate (5 mg daily)
Study: 16818571
Drug: Vitamin B6
Normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B6 (100 mg daily)
Study: 1319619
Drug: Logiparin (2,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Logiparin (2,500 anti-Xa units once daily)
Study: 1319619
Drug: Logiparin (3,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Logiparin (3,500 anti-Xa units once daily)
Study: 1319619
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (5,000 IU twice daily)
Study: 24423921
Drug: Axitinib 10
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Axitinib 10 mg b.i.d. combined with FOLFIRI or FOLFOX
Study: 18031439
Drug: Nonsubmerged surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsubmerged surgical technique (198 implants)
Study: 18031439
Drug: Submerged surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Submerged surgical technique (206 implants)
Study: 16563590
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg citalopram
Study: 12588933
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg reboxetine
Study: 29471300
Drug: Zevalin (Yttrium-90-Ibritumomab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zevalin (Yttrium-90-Ibritumomab Tiuxetan) after 2 cycles of ESHAP chemotherapy
Study: 19699454
Drug: 5mg of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg of oxybutynin in sublingual form (Group O)
Study: 1397884
Drug: Norfloxacin, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin, 400 mg orally or through a nasogastric tube, twice daily for 7 days
Study: 3892729
Drug: Ketoconazole 400
Normalized name: ketoconazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 400 mg/d
Study: 29627596
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (1200 mg/day of eicosapentaenoic acid and 600 mg/day of docosahexaenoic acid)
Study: 23513399
Drug: Placebo pills
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pills
Study: 8465360
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg daily
Study: 12060436
Drug: Oxybutynin 5
Normalized name: oxyBUTYnin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin 5 mg bid
Study: 10417452
Drug: Morphine 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.75 mg plus alfentanil 0.125 mg (Group MA)
Study: 10417452
Drug: Morphine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 1.5 mg alone (Group M)
Study: 2107519
Drug: Concurrent administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent administration of Haemophilus influenzae type b conjugate vaccine with diphtheria-tetanus-pertussis and oral poliovirus vaccines
Study: 424753
Drug: Fentanyl (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (intravenous administration)
Study: 26522499
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy plus Pulmonary Rehabilitation (PR)
Study: 21370402
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy followed by tumor resection
Study: 21370402
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and tumor resection
Study: 19135570
Drug: Doxycycline 200
Normalized name: doxycycline 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 200 mg given 4 hours before D&E (Group 1)
Study: 3071603
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (Group A)
Study: 14750898
Drug: Standard-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose chemotherapy
Study: 19824078
Drug: Betaine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaine (20 g daily)
Study: 16978993
Drug: Facilitated angioplasty
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facilitated angioplasty with full- or half-dose thrombolysis
Study: 11704586
Drug: Inhaled IL-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled IL-5 (15 microg)
Study: 11704586
Drug: Intravenous IL-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous IL-5 (2 microg)
Study: 3318971
Drug: Almitrine bismesylate
Normalized name: almitrine dimesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine bismesylate (100-200 mg per day orally in two divided doses)
Study: 24994597
Drug: Melacine vaccine
Normalized name: melamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melacine vaccine for 2 years
Study: 24994597
Drug: Melacine vaccine
Normalized name: melamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melacine vaccine in HLA-A2 and/or HLA-Cw3 serotype patients (n = 178)
Study: 17251232
Drug: Standard bronchodilator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard bronchodilator treatment (SBDT) only
Study: 10216540
Drug: PGE1 infusion
Normalized name: PGE1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PGE1 infusion started at 0.05 microgram/kg/min, decreased to 0.005-0.01 microgram/kg/min for maintenance.
Study: 10216540
Drug: PGE1 infusion
Normalized name: PGE1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PGE1 infusion for Group IV (left ventricular volume improvement).
Study: 22490713
Drug: High-dose tirofiban
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose tirofiban
Study: 22944274
Drug: Normal-dose tirofiban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal-dose tirofiban
Study: 9234663
Drug: Stepwise dobutamine-infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepwise dobutamine-infusion protocol (10-40 microg/kg/min, 3-min intervals)
Study: 9234663
Drug: Continuous dobutamine-infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous dobutamine-infusion protocol (10 microg/kg/min for 12 min)
Study: 9234663
Drug: Stepwise dobutamine-infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepwise dobutamine-infusion protocol
Study: 7900237
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with low-dose IL-2 (3 million IU/day subcutaneously for 6 days/week for 4 weeks) plus melatonin (40 mg/day orally, starting 7 days before IL-2)
Study: 7900237
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with low-dose IL-2 plus MLT
Study: 31621254
Drug: Auricular acupuncture
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular acupuncture combined with dydrogesterone (10 mg orally twice a day until 12 weeks of pregnancy)
Study: 22964169
Drug: Sorafenib 400mg
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorafenib 400mg twice daily plus subcutaneous IFN, 9 million units (MU) three times a week (Arm A)
Study: 22964169
Drug: Sorafenib 400mg
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorafenib 400mg twice daily plus subcutaneous IFN, 3 MU five times a week (Arm B)
Study: 21221804
Drug: Daily CIFN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily CIFN (15 mcg/day SQ) and RBV (1‐1.2 g/d PO) for 52 weeks (group A, n = 33)
Study: 21221804
Drug: Daily CIFN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily CIFN (15 mcg/day SQ) and RBV (1‐1.2 g/d PO) for 52-72 weeks (group B, n = 31)
Study: 21221804
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (n=64)
Study: 18828055
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose ceftriaxone
Study: 18828055
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ampiclox, gentamicin, and metronidazole
Study: 23946704
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg modafinil once daily for 4 weeks
Study: 23946704
Drug: Placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for 4 weeks
Study: 21251795
Drug: Matched-placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched-placebo administration
Study: 21251795
Drug: Immediate-release opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release opioid administration in high PCS scorers
Study: 21251795
Drug: Matched-placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched-placebo administration in high PCS scorers
Study: 21251795
Drug: Immediate-release opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release opioid administration in low PCS scorers
Study: 19091796
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A (240 mg in 4 doses)
Study: 15093907
Drug: High-dose radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose radiotherapy (64.8 Gy in 36 fractions)
Study: 15093907
Drug: Low-dose radiotherapy
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose radiotherapy (50.4 Gy in 28 fractions)
Study: 28130659
Drug: Pitavastatin 1-4
Normalized name: pitavastatin
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pitavastatin 1-4 mg once daily
Study: 21289249
Drug: D(2) dosing
Normalized name: Vitamin D-2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D(2) dosing
Study: 21289249
Drug: D(3) dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: D(3) dosing